December 9, 2024

Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse – GSK

December 9, 2024

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

New England Journal of Medicine, Ahead of Print.

December 9, 2024

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma – The New England Journal of Medicine

December 9, 2024

Dozens of Presentations Advance Multiple Myeloma Research at the American Society for Hematology Meeting – University of Miami

December 7, 2024

Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts – Memorial Sloan Kettering Cancer Center